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Summary Purpose: Angiogenesis plays an essential role in
tumor development, invasion and metastasis. We evaluated
the efficacy and safety of dual angiogenesis blockade with
bevacizumab and sorafenib in patients with metastatic breast
cancer. Patients and Methods: Patients who had received no
more than 2 prior chemotherapy regimens in any setting
were treated with sorafenib 200 mg as a single oral dose
daily plus bevacizumab intravenously 5 mg/kg every other
week. Response was assessed by Response Evaluation
Criteria in Solid Tumors (RECIST). The primary endpoint
was progression free survival (PFS). Results: Eighteen pa-
tients were enrolled. Median age was 56 yo, all had good
performance status KPS of 0 or 1, and 17 patients had
received 1 or 2 prior chemotherapy regimens. Median PFS
was 2.8 months. There were no complete or partial re-
sponses; 3 patients had stable disease for >6 months. Tox-
icity was substantial with 9 (50 %) patients reporting Grade
3 toxicity. Seven (39 %) patients discontinued therapy due
to adverse events including hypertension (N=2), GI toxicity
(N=1), sensory neuropathy (N=1), rash (N=1), pain (N=1)
and wound complication (N=1). Given the lack of clear
efficacy and increased toxicity, accrual was terminated.
Conclusion: The combination of sorafenib and bevacizumab
has substantial toxicity and minimal efficacy in patients with
previously treated metastatic breast cancer. Further study of
this combination is not recommended.
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Metastatic breast cancer is generally incurable with only a few
patients achieving long-term survival after standard chemo-
therapy [1]. Though an expanding arsenal of active agents is
available for the treatment of metastatic disease, overall sur-
vival has changed little during the last half century.
Extensive laboratory data suggests that angiogenesis plays
an essential role in breast cancer development, invasion and
metastasis. Of the identified angiogenic factors, vascular en-
dothelial growth factor (VEGF; also known as vascular per-
meability factor) is the most potent and specific and is a
crucial regulator of both normal and pathologic angiogenesis
[2]. Bevacizumab, a monoclonal antibody directed against
VEGF-A, has modest activity as a single agent but improves
response rate and PFS but not overall survival when adminis-
tered in combination with chemotherapy.
There is also strong evidence supporting a role for
platelet-derived growth factor receptor (PDGFR) signaling
in breast cancer autocrine and paracrine signaling. PDGFR
has been detected in the stromal compartment of many
human breast cancers by immunostaining [3]. High levels
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of immunostaining for PDGF receptor ligands, PDGF-A
and PDGF-B, have been commonly detected directly on
breast cancer cells in archival human tumors [4].
Sorafenib is a multikinase inhibitor targeting several
serine/threonine and receptor tyrosine kinase receptors in-
cluding VEGF, PDGF and the mitogen activated protein
kinases (MAPK) pathway [5]. Sorafenib monotherapy
(400 mg twice daily) had little activity in patients with
previously treated metastatic breast cancer in two previously
reported trials [6]. The addition of sorafenib to chemother-
apy drugs is currently being investigated in the TIES (Trials
to Investigate the Effects of Sorafenib in Breast Cancer)
program. Two of these studies have already been completed
and presented—the NU 07B1 and the SOLTI-0701 trials.
The SOLTI trial reported by Baselga et al. showed a signif-
icant clinical benefit with the combination of capecitabine
and sorafenib when compared to capecitabine monotherapy,
PFS of median, 6.4 vs. 4.1 mo; hazard ratio 0.58; 1-sided p=
0.0006. This was achieved at the expense of more toxicity.
The NU07B1 trial reported by Gradishar et al., compared
the safety and efficacy of sorafenib in combination with
paclitaxel vs paclitaxel with placebo. Results showed no
improvement in PFS which was the primary endpoint [7–9].
Considering that pro-angiogenic peptides are produced in
increasing numbers as tumors progress, we hypothesized
that combined inhibition of multiple angiogenesis pathways,
whether serial or parallel, may increased activity. Results of
a phase I trial of a combination of bevacizumab and
sorafenib in 39 patients with a variety of tumour types (Azad
et al., 2008a, b) has already been reported including ovarian
cancer. Their results showed an unexpectedly high partial
response rate (PR 1⁄4 46 %) in patients with relapsed EOC
compared with 16–21 % response rate reported with
bevacizumab alone [10]. Our trial evaluates combined
VEGF inhibition with sorafenib and bevacizumab in pre-
treated patients with advanced breast cancer.
Patients and methods
Patient eligibility
Eligible patients, ≥18 years old, had histologically con-
firmed adenocarcinoma of the breast with evidence of met-
astatic disease, measurable according to RECIST 1.0
criteria. Patients were also required to have an ECOG per-
formance status of 0 or 1 as well as adequate hematologic,
renal and hepatic function. Patients with HER2 positive (3+
by immunohistochemistry or gene amplification by fluores-
cence in situ hybridization) disease must have received prior
trastuzumab therapy. Patients could not have received more
than 2 prior chemotherapy regimens, considering all adju-
vant and neoadjuvant therapy as one regimen. Prior
hormonal therapy was allowed. Prior radiation therapy was
allowed as long as the irradiated area is not the only source
of evaluable disease.
The study was performed in compliance of good clinical
practice, the Helsinki Declaration, and federal and institu-
tional guidelines. Ethical review boards at each institution
approved the trial protocol prior to patient enrollment. All
patients provided written informed consent.
Treatment plan
Sorafenib was administered orally at 200 mg daily;
sorafenib dose could be increased to 200 mg twice daily in
patients without significant toxicity in the first two cycles.
Bevacizumab was given intravenously at 5 mg/kg every
other week. One cycle was considered to be 28 days. Treat-
ment continued until disease progression or unacceptable
toxicity intervened.
Toxicities were evaluated using the Common Terminology
Criteria for Adverse Events (CTCAE) version 3. Patients were
evaluated clinically every week for the first cycle than every
other week for the subsequent cycle. Hypertension was mon-
itored weekly during the first cycle, then prior to each
bevacizumab infusion. Urine protein creatinine ratio or dip-
stick urinalysis was performed every 8 weeks. Complete
blood count and serum chemistries were obtained before each
cycle. No Bevacizumab dose reduction was allowed and no
dose modification was specified for grades 1/2 toxicities.
Bevacizumab was discontinued for any arterial thromboem-
bolic event, all grade 4 non hematologic toxicities, and grades
3 and 4 allergic reactions. Bevacizumab therapy was held for
other clinically relevant grade 3 toxicities, then resumed upon
resolution or adequate control. Sorafenib was held for all
grade 3/4 toxicities and, depending on clinical severity, either
permanently discontinued or restarted at a lower dose upon
resolution.
Disease status was assessed according to RECIST criteria
at the end of every third cycle.
Statistical considerations
The primary endpoint was PFS, defined as the time from
first treatment to disease progression or death from any
cause. The study was designed to detect an improvement
from median PFS of 3 months based on the previous expe-
rience with bevacizumab monotherapy to 5 months. Assum-
ing a type I error of 5 % and 90 % power, 39 patients were
required. To account for potential dropouts and unevaluable
patients, a total sample size of 42 patients was initially
planned. Based on the toxicity experience in the first 18
patients, an unplanned analysis of PFS was requested. When
this failed to suggest significant benefit for the combined
regimen, the study was terminated.
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Secondary endpoints included overall response rate
(ORR), clinical benefit response defined as the percentage of
evaluable patients with confirmed complete response (CR),
partial response (PR), or stable disease (SD) for at least
6 months (CR+PR+SD), and safety. The median and range
of continuous variables are presented. Frequencies and per-
cents of categorical variables are provided. Exact binomial
95 % confidence intervals were calculated for response. The
method of Kaplan-Meier was used to calculate median dura-
tion of follow-up, survival, and progression free survival [11].
Results
Patient characteristics
From October 2007 toMarch 2009, 18 patients were enrolled.
Patient characteristics are shown in Table 1. Nearly half of the
patients had triple negative (ER-, PR-, HER2-) disease, and
most had received 1 or 2 prior chemotherapy regimens.
Efficacy
Median PFS was 2.8 months, 95 % CI (1.8–6.1). There were
no complete or partial responses. Six patients had stable
disease but only three (20 %) were stable for 6 months or
more. Three patients died within 30 days of last therapy.
Toxicity
In general, this toxicity was substantial. Although no grade 4
toxicity was noted, 9 (50 % of patients reported grade 3
toxicity (Table 2). Hypertension was common with 14
(78 %) patients experiencing grade 2 or 3 toxicity. GI toxicity,
sensory neuropathy, rash, and pain were also relatively com-
mon. Seven patients discontinued therapy due to toxicity;
reasons for treatment discontinuation were uncontrolled hy-
pertension (n=2), nausea (n=1), neuropathy (n=1), pain (n=
1), rash (n=1) and wound complications (n=1). One patient
had a grade 3 hypersensitivity reaction; however patient was
able to continue with treatment with premedication. No he-
matologic toxicities were reported, however elevation in the
liver transaminases were noted in two patients.
Discussion
This report summarizes the results of the study of the com-
bination of Sorafenib with Bevacizumab in previously treat-
ed patients with metastatic breast cancer. Our results show
that the combination of the two angiogenic inhibitors in
this patient population is poorly tolerated. All patients
experienced some kind of toxicity and in half of them
the toxicity was reported to be grade 3. The trial was
stopped early because of the poor safety profile as well
as the lack of significant efficacy of this combination
over bevacizumab alone in the short follow up period
where it was evaluated.
The significant toxicity of this combination questions the
safety of dual VEGF blockade or VEGF/PDGF inhibition.
This problem had been encountered in the earlier phase I
studies of Sorafenib and Bevacizumab where a recurrent
theme was the inability to dose escalate those drugs and
where the maximal tolerated dose ended up having to be the
Table 1 Patient characteristics (n=18)
Median Range
Age 56 years 33–75 years
Median Mean
















ER+/PR+/HER2 unknown 2 11.1
Prior chemotherapy regimens
0 1 5.6
1 or 2 17 94
Prior hormonal therapy 9 50.0
Prior radiation therapy 11 61.1
Table 2 Treatment-related toxic effects
Toxicity
category
Grade 1 Grade 2 Grade 3 Total
n % n % n % n %
GI 6 33.3 7 38.9 0 0 13 72.2
Derm 4 22.2 2 11.1 1 5.6 7 38.9
CV 0 0 11 61.1 4 22.2 15 83.3
Neuro 2 11.1 0 0 1 5.6 3 16.7
Lab 1 5.6 1 5.6 2 11.1 4 22.2
Other 6 33.3 5 27.8 5 27.8 16 88.9
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initial dose which is usually much lower than the efficacious
dose [10, 12]. When it comes to double angiogenesis block-
ade, our experience also mirrors some of the other combi-
nations like with the combination of bevacizumab with
Sunitinib. Several studies with this combination in solid
tumors had to be halted secondary to significant side effects
including anemia, myelosuppression, fatigue and gastroin-
testinal complications. In a phase I study by Feldman et al.,
Sunitinib and bevacizumab was tried in patients with ad-
vanced renal cell carcinoma, again significant toxicity was
encountered, with similar toxicity profile with the one we
encountered with hypertension, fatigue and GI problems
being very common [13]. Other studies reflect the same
reality. In a recent phase 3 trial the SABRE-B study evalu-
ated the triple combination of paclitaxel, bevacizumab and
Sunitinib in metastatic breast cancer, that study accrual was
also stopped because poor tolerability and inability to dose
escalate sunitinib as planned secondary to the toxicity pro-
file [14]. Many other trials reproduced similar results [15,
16]. The broad spectrum of signaling inhibition of the TKI’s
brought increased toxicity with dose reductions and limited
drug exposure that ultimately, we believe, hindered activity.
Overall results with VEGF TKIs in MBC have been
disappointing. The broader spectrum of activity had provid-
ed hope for greater efficacy. However, with that broader
profile comes increased toxicity, need for dose reductions
and the general inability to combine with chemotherapy.
In conclusion drug development is a challenging task; the
combination of biologics is very unpredictable and could be
misleading. A deeper understanding of the biology of breast
cancer and its underlying molecular identity is warranted
prior to embarking into further targeted therapy trials.
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